Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Emerging Therapies
Emerging Therapies
Adding the BCL-2 Inhibitor Venetoclax to Treatment Regimen Promising in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Emerging Therapies
,
In the News
“Smart Bomb” First-in-Class Drug Rova-T Promising Novel Therapy for Small-Cell Lung Cancer
Phoebe Starr
Read More
Emerging Therapies
The Oncology Drug Pipeline Shows No Evidence of Slowing Down
Wayne Kuznar
Read More
Emerging Therapies
The Hematologic Drug Pipeline: Exciting New Treatment Options Looming
Phoebe Starr
Read More
Emerging Therapies
Midostaurin the First Targeted Therapy to Improve Survival in AML: Potentially Practice-Changing
Phoebe Starr
Read More
Emerging Therapies
Venetoclax Shows Strong Activity in CLL
Phoebe Starr
Read More
Emerging Therapies
Nivolumab Beats Docetaxel as Second-Line Therapy for Patients with NSCLC
Phoebe Starr
Read More
Emerging Therapies
Oncology Pipeline Full, and Not Just with Immunotherapies
Caroline Helwick
,
Wayne Kuznar
Read More
Emerging Therapies
CAR-T Cells: The Transplants of the Future
Chase Doyle
Read More
Emerging Therapies
Encouraging Results for Pembrolizumab in Head and Neck Cancer
Phoebe Starr
Read More
1
2
3
4
5
6
7
Page 4 of 7
Results 31 - 40 of 67